APCR
0.004
300%
IMC
0.039
-40%
MEU
0.12
71.4%
JNS
0.058
-38.9%
IFG
0.017
70%
TMB
0.049
-34.7%
VRC
0.01
66.7%
MIO
0.02
-33.3%
ALV
0.085
63.5%
PET
0.014
-30%
CTN
0.003
50%
CRS
0.091
-27.2%
IMM
0.375
47.1%
DTM
0.035
-27.1%
PER
0.01
42.9%
BAP
1.76
-25.1%
AUA
0.04
37.9%
NES
0.006
-25%
STV
0.011
37.5%
A11
0.155
-24.4%
ELS
2.67
35.5%
WNX
0.125
-24.2%
AGY
0.095
33.8%
AM5
0.007
-22.2%
ALY
0.012
33.3%
KLV
0.007
-22.2%
CHM
0.004
33.3%
NFL
0.11
-21.4%
RHY
0.105
32.9%
MNB
0.023
-20.7%
AR9
0.13
32.7%
CKA
0.054
-20.6%
ASL
2.43
31.4%
HVY
0.5
-20%
X2M
0.013
30%
TYX
0.004
-20%
LRM
0.031
29.2%
LKY
0.205
-19.6%
SPD
1.565
28.8%
SUM
0.033
-19.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BOT successful completion of human factors validation study

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) announces that the Company has successfully completed the planned human factors validation study assessing the revised Instructions for Use for Sofpironium Bromide gel https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02753854-6A1186430 #shorts